In vitro activity of ceftazidime, cefotaxime and piperacillin against multi-resistant gram-negative bacteria tested with a modified agar dilution method

1982 ◽  
Vol 1 (3) ◽  
pp. 166-170 ◽  
Author(s):  
J. A. A. Hoogkamp-Korstanje ◽  
C. A. Meijer
Keyword(s):  
Vitro Activity ◽  
Dilution Method ◽  
Agar Dilution Method ◽  
Gram Negative Bacteria ◽  
In Vitro Activity ◽  
Gram Negative ◽  
Agar Dilution

scholarly journals In Vitro Activity of Moxifloxacin against 923 Anaerobes Isolated from Human Intra-Abdominal Infections

2006 ◽  
Vol 50 (1) ◽  
pp. 148-155 ◽  
Author(s):  
Ellie J. C. Goldstein ◽  
Diane M. Citron ◽  
Yumi A. Warren ◽  
Kerin L. Tyrrell ◽  
C. Vreni Merriam ◽  
...  
Keyword(s):  
Bacteroides Fragilis ◽  
Vitro Activity ◽  
Dilution Method ◽  
Agar Dilution Method ◽  
Species Variation ◽  
In Vitro Activity ◽  
Resistant Species ◽  
Agar Dilution ◽  
Abdominal Infections

ABSTRACT The in vitro activity of moxifloxacin against 923 recent anaerobic isolates obtained from pretreatment cultures in patients with complicated intra-abdominal infections was studied using the CLSI M11-A-6 agar dilution method. Moxifloxacin was active against 87% (96 of 110) Bacteroides fragilis strains at ≤1 μg/ml and 87% (79 of 90) B. thetaiotaomicron strains at ≤2 μg/ml. Species variation was seen, with B. uniformis, B. vulgatus, Clostridium clostridioforme, and C. symbiosum being least susceptible and accounting for most of the resistant isolates; excluding the aforementioned four resistant species, 86% (303 of 363) of Bacteroides species isolates and 94% (417 of 450) of all other genera and species were susceptible to ≤2 μg/ml of moxifloxacin. Overall, moxifloxacin was active against 763 of 923 (83%) of strains at ≤2 μg/ml, supporting its use as a monotherapy for some community-acquired intra-abdominal infections.

scholarly journals Comparative In Vitro Activities of Retapamulin (SB-275833) against 141 Clinical Isolates of Propionibacterium spp., Including 117 P. acnes Isolates

2006 ◽  
Vol 50 (1) ◽  
pp. 379-381 ◽  
Author(s):  
Ellie J. C. Goldstein ◽  
Diane M. Citron ◽  
C. Vreni Merriam ◽  
Yumi A. Warren ◽  
Kerin L. Tyrrell ◽  
...  
Keyword(s):  
Active Agent ◽  
Vitro Activity ◽  
Clinical Isolates ◽  
Dilution Method ◽  
Agar Dilution Method ◽  
In Vitro Activity ◽  
Agar Dilution ◽  
Multiresistant Strains

ABSTRACT Using the NCCLS agar dilution method, we studied the in vitro activity of retapamulin (SB-275833) against 141 clinical isolates of Propionibacterium species, including seven multiresistant strains, and found retapamulin to be the most active agent among those tested with MICs of ≤1 μg/ml against all isolates.

scholarly journals Comparison of in vitro activity of various macrolides against Helicobacter pylori

2018 ◽  
Vol 20 (3) ◽  
pp. 192-197
Author(s):  
Natalya N. Dekhnich ◽  
Nataly V. Ivanchik ◽  
Roman S. Kozlov
Keyword(s):  
Vitro Activity ◽  
Dilution Method ◽  
Agar Dilution Method ◽  
In Vitro Activity ◽  
Minimal Inhibitory Concentrations ◽  
Biopsy Specimens ◽  
Agar Dilution ◽  
H Pylori ◽  
Comparison Of The Results

Objective. Compare the in vitro activity of clarithromycin, erythromycin, azithromycin and josamycin against the collection of H. pylori strains isolated in 2010–2017 in Smolensk. Materials and Methods. H. pylori strains were collected prospectively from biopsy specimens of the gastric mucosa. Antimicrobial susceptibility testing of H. pylori was performed by the agar dilution method. Interpretation of the results of the susceptibility determination for clarithromycin was carried out in accordance with the recommendations of EUCAST (v 8.0) 2018. The resistance breakpoints for erythromycin, azithromycin, and josamycin were all set at ≥1.0 mg/L. For comparison of the results, the value of the minimal inhibitory concentrations of the tested antibiotic inhibiting the growth of 50% (MIC50) and 90% (MIC90) of H. pylori strains was used. Results. A total of 276 H. pylori strains were tested. 90% of the MIC values of clarithromycin were in the range from 0.015 to 0.125 mg/l. The percentages of resistance were as follows: clarithromycin 5.1%, azithromycin 7.5%, erythromycin 8%, josamycin 23.2%. Clarithromycin demonstrated significantly higher activity in suppressing the growth of H. pylori strains than azithromycin, erythromycin, and josamycin. Conclusions. Among the tested macrolide antibiotics maximal anti-H. pylori activity in vitro was observed in clarithromycin.

scholarly journals Comparative In Vitro Activity of Ceftobiprole against Staphylococci Displaying Normal and Small-Colony Variant Phenotypes

2005 ◽  
Vol 49 (10) ◽  
pp. 4372-4374 ◽  
Author(s):  
Christof von Eiff ◽  
Alexander W. Friedrich ◽  
Karsten Becker ◽  
Georg Peters
Keyword(s):  
Staphylococcus Aureus ◽  
Vitro Activity ◽  
Dilution Method ◽  
Agar Dilution Method ◽  
In Vitro Activity ◽  
Small Colony Variant ◽  
Antistaphylococcal Activity ◽  
Agar Dilution ◽  
Small Colony

ABSTRACT The antistaphylococcal activity of ceftobiprole was compared with those of cefuroxime, linezolid, and moxifloxacin by using the agar dilution method. Apart from three strains with small-colony variant phenotypes, all Staphylococcus aureus isolates tested were inhibited by ≤2 μg/ml of ceftobiprole. This compound exhibited an excellent antistaphylococcal activity, comparable to that of linezolid.

scholarly journals In Vitro and In Vivo Antibacterial Activities of DW-224a, a New Fluoronaphthyridone

2006 ◽  
Vol 50 (6) ◽  
pp. 2261-2264 ◽  
Author(s):  
Hee-Soo Park ◽  
Hyun-Joo Kim ◽  
Min-Jung Seol ◽  
Dong-Rack Choi ◽  
Eung-Chil Choi ◽  
...  
Keyword(s):  
Antibacterial Activities ◽  
The Other ◽  
Vitro Activity ◽  
Gram Negative Bacteria ◽  
In Vitro Activity ◽  
Gram Positive ◽  
Gram Negative ◽  
Gram Positive Bacteria

ABSTRACT DW-224a showed the most potent in vitro activity among the quinolone compounds tested against clinical isolates of gram-positive bacteria. Against gram-negative bacteria, DW-224a was slightly less active than the other fluoroquinolones. The in vivo activities of DW-224a against gram-positive bacteria were more potent than those of other quinolones.

In vitro activity of BAL9141 against clinical isolates of gram-negative bacteria

2004 ◽  
Vol 48 (1) ◽  
pp. 73-75 ◽  
Author(s):  
Nicolas C. Issa ◽  
Mark S. Rouse ◽  
Kerryl E. Piper ◽  
Walter R. Wilson ◽  
James M. Steckelberg ◽  
...  
Keyword(s):  
Vitro Activity ◽  
Clinical Isolates ◽  
Gram Negative Bacteria ◽  
In Vitro Activity ◽  
Gram Negative

In Vitro Activity of Gepotidacin Against Gram-negative and Gram-positive Anaerobes

2021 ◽  
Author(s):  
Meredith A. Hackel ◽  
James A. Karlowsky ◽  
Michele A. Canino ◽  
Daniel F. Sahm ◽  
Nicole E. Scangarella-Oman
Keyword(s):  
Clinical Trials ◽  
Vitro Activity ◽  
Phase Iii ◽  
In Vitro Activity ◽  
Gram Positive ◽  
Gram Negative ◽  
Phase Iii Clinical Trials ◽  
Agar Dilution

Gepotidacin (formerly GSK2140944) is a first in class triazaacenaphthylene antibacterial currently in Phase III clinical trials. When tested against Gram-negative ( n =333) and Gram-positive ( n =225) anaerobes by agar dilution, gepotidacin inhibited 90% of isolates (MIC 90 ) at concentrations of 4 and 2 μg/ml, respectively. Given gepotidacin’s in vitro activity against the anaerobic isolates tested, further study is warranted to better understand gepotidacin’s utility in the treatment of infections caused by clinically relevant anaerobic organisms.

Sign in / Sign up

Export Citation Format

Share Document